spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  anti-platelet 

 HSMN NewsFeed - 6 Sep 2022
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 30 Jun 2021
Abbott's XIENCE Stent Receives FDA Approval for Shortest Blood Thinner Course for High Bleeding Risk Patients
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 12 May 2020
CytoSorb(R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
Devices Regulatory
 HSMN NewsFeed - 27 Apr 2020
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
Devices Personnel
 HSMN NewsFeed - 29 Jan 2020
CytoSorb(R) is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
Devices Regulatory Product Launch
 HSMN NewsFeed - 1 Nov 2019
CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
Devices
 HSMN NewsFeed - 25 Oct 2018
EYLEA(R) (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Sep 2018
FDA Approves CroFab(R) Product Improvements
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2018
Nobles Medical Technologies II Showcases Noblestitch(TM) PFO Closure At EuroPCR
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Sep 2017
Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 5 Oct 2015
Boston Scientific Receives FDA Approval For SYNERGY(TM) Bioabsorbable Polymer Drug-Eluting Stent System
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 21 Jul 2015
Ophthotech Announces New Senior Leadership Appointments
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 17 Oct 2014
EYLEA(R) (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 27 Jun 2014
EYLEA(R) (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment due to Diabetic Macular Edema in the European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 May 2014
FDA Approves EPANOVA for the Treatment of Adults with Severe Hypertriglyceridemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Feb 2014
Two-Year Results From Phase 3 VISTA Trial of EYLEA(R) (aflibercept) Injection for the Treatment of Diabetic Macular Edema Show Sustained Improvement in Vision
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 30 Oct 2013
The Medicines Company's EUROMAX Trial of Angiox(R) (Bivalirudin) in Heart Attack Meets All Prespecified Endpoints
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 28 Aug 2013
FDA Accepts Boehringer Ingelheim's Supplemental New Drug Application for Use of Dabigatran Etexilate Mesylate in Deep Vein Thrombosis and Pulmonary Embolism
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jun 2013
AngioScore Announces Completion of Enrollment in Drug-Coated AngioSculpt(R) Scoring Balloon Catheter First-in-Human Study
Devices Interventional Cardiology
 HSMN NewsFeed - 29 May 2013
Ophthotech Raises $175 Million to Finance the Pivotal Phase 3 Program for Fovista(TM) Anti-PDGF Combination Therapy in Wet AMD
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 13 Nov 2012
Nanosphere Receives FDA Clearance to Market Test for Detection of CYP2C19 Mutations Affecting Drug Metabolism
Diagnostics FDA
 HSMN NewsFeed - 7 Nov 2012
URGENT NOTICE -- DRUG RECALL: Boehringer Ingelheim Pharmaceuticals, Inc. Initiates a Voluntary Recall of a Single Manufacturing Lot of Pradaxa(R) (dabigatran etexilate mesylate) Capsules 75mg in the U.S. and Puerto Rico
Biopharmaceuticals Cardiology Product Recall
 HSMN NewsFeed - 24 Oct 2012
PROMUS Element(TM) and PROMUS Element(TM) Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 20 Aug 2012
Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 16 May 2012
Elixir Medical Announces Excellent Results from DESolve I First-In-Man Study for the Fully Bioresorbable Drug Eluting Coronary Scaffold System
Devices Interventional Cardiology
 HSMN NewsFeed - 15 May 2012
Abbott's XIENCE PRIME(TM) and XIENCE V(R) Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 15 May 2012
Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study
Devices Interventional Cardiology
 HSMN NewsFeed - 14 Dec 2011
AngioScore Announces Successful Initiation of Enrollment in Drug-Coated AngioSculpt(R) Scoring Balloon Catheter First-in-Human Study
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Aug 2011
Boehringer Ingelheim to Launch RE-ALIGN Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 18 May 2011
Favorable Clinical Study Results Reported With Dual Anti-Platelet Therapy After LAA Closure With WATCHMAN(R) Device
Devices Interventional Cardiology
 HSMN NewsFeed - 11 May 2011
Accumetrics Signs National Distribution Agreement with Cardinal Health
Diagnostics Personalized Medicine Cardiology Distribution
 HSMN NewsFeed - 22 Feb 2011
Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Jan 2011
Abbott Receives CE Mark Approval for World's First Drug Eluting Bioresorbable Vascular Scaffold for Treatment of Coronary Artery Disease
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 16 Nov 2010
Blue Medical Receives European CE Mark Approvals for Drug Eluting Balloon and Stent on Drug Eluting Balloon Combination Device
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 20 Oct 2010
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Neurology FDA
 HSMN NewsFeed - 8 Jul 2010
Gore Provides Update on Patent Foramen Ovale (PFO) Stroke Study
Devices Interventional Cardiology Neurology
 HSMN NewsFeed - 6 May 2010
The New England Journal of Medicine Publication of SPIRIT IV Trial Results Confirm Superior Safety and Efficacy of Abbott's XIENCE V(R) Drug Eluting Stent Compared to TAXUS
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Apr 2010
OrbusNeich Announces Full Availability of Genous(TM) Bio-engineered Cobalt Chromium Stent Following CE Mark Approval
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 9 Mar 2010
Bristol-Myers Squibb and AstraZeneca Announce the Commencement of the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus Trial (SAVOR-TIMI 53)
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 3 Mar 2010
Edward R. Teitel, MD, JD Becomes Chairman of Urigen
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 31 Aug 2009
First Patient Enrolled in CYPRESS, a Dual Antiplatelet Therapy Trial with the CYPHER(R) Sirolimus-Eluting Coronary Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Aug 2009
Abbott Expands XIENCE V(R) USA Trial to Enroll Patients into Landmark Dual Anti-Platelet Therapy (DAPT) Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 19 May 2009
NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results to Taxus Liberte Stent in Pivotal Clinical Trial
Devices Interventional Cardiology
 HSMN NewsFeed - 13 May 2009
The Medicines Company Discontinues Phase 3 CHAMPION Clinical Trial Program of Cangrelor
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 7 Apr 2009
Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients
Devices Cardiology
 HSMN NewsFeed - 27 Jan 2009
Archemix Announces Continued Progress with Business Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jan 2009
New Research Suggests Platelet Stickiness May be the Single Most Important Risk Factor in Patients Treated with Coronary Stents - Findings May be Applicable to Anyone with Vascular Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Jan 2009
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Dec 2008
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 6 Nov 2008
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 3 Nov 2008
DAIICHI SANKYO Acquires Merck Serono's Cardio-Metabolism Sales Force and Products in Turkey
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 13 Oct 2008
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Devices Interventional Cardiology
 HSMN NewsFeed - 7 Oct 2008
CeloNova BioSciences to Showcase the CE-Marked CATANIA(TM) Coronary Stent System Featuring NanoThin Polyzene(R)-F at TCT Debut
Devices Interventional Cardiology
 HSMN NewsFeed - 15 Sep 2008
MIV Therapeutics VESTAsync(TM) Drug-Eluting Stent Trials Progress
Devices Interventional Cardiology
 HSMN NewsFeed - 3 Sep 2008
Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Sep 2008
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 2 Sep 2008
New Data Shows Anticlotting Medicine, AGGRASTAT(R), Lowers Incidence of Heart Attack, in Patients Who Respond Poorly to Aspirin or Clopidogrel, after Elective Coronary Angioplasty
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 10 Jun 2008
Otsuka and UCB agreed to co-develop and co-promote Keppra(R) and Cimzia(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 28 Apr 2008
Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
Devices Cardiology
 HSMN NewsFeed - 22 Apr 2008
Archemix' ARC1779 Granted Orphan Designation for the Treatment of TTP, a Life-Threatening Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Mar 2008
BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 29 Mar 2008
ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 21 Jan 2008
Super-Thin Drug-Free Coating 'Hides' Stent as It Unblocks Heart Arteries
Devices Interventional Cardiology
 HSMN NewsFeed - 20 Jan 2008
CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Dec 2007
Heartscape Technologies Appoints Former Medtronic Executive to Role as Chairman and Independent Director
Devices Personnel
 HSMN NewsFeed - 10 Oct 2007
FDA Advisory Committee Recommends Medtronic's Endeavor(R) Drug-Eluting Stent for Approval
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 13 Aug 2007
Ophthotech Raises $36 Million; In-Licenses Two Compounds for Macular Degeneration
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 27 Jul 2007
OSI Pharmaceuticals Announces Agreement to Divest Anti-Platelet Derived Growth Factor (PDGF) Program
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 9 Jul 2007
St. Jude Medical Announces First Enrollment in Study To Understand Appropriate Anti-Clotting Therapy After Tissue Heart Valve Implant
Devices Cardiology
 HSMN NewsFeed - 22 May 2007
ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 21 May 2007
Medtronic Announces Start of 8,800-Patient Clinical Trial Evaluating Drug-Eluting Stent Safety
Devices Interventional Cardiology
 HSMN NewsFeed - 2 May 2007
FDA Approves FRAGMIN(R) as First Low-Molecular-Weight Heparin for Extended Treatment to Reduce the Recurrence of Blood Clots in Patients with Cancer
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Apr 2007
Volcano Corporation Reports Use of IVUS Increasing as Physicians Refocus on Stent Technique
Devices Interventional Cardiology
 HSMN NewsFeed - 26 Mar 2007
Two-Year Patient Registry Results Support Safety and Efficacy of CYPHER(R) Sirolimus-Eluting Coronary Stent in 'Real World' Uses
Devices Interventional Cardiology
 HSMN NewsFeed - 23 Mar 2007
Boston Scientific Announces Industry-Leading Program to Improve Anti-Platelet Compliance for DES Patients
Devices Interventional Cardiology
 HSMN NewsFeed - 12 Feb 2007
Multiple Articles in the New England Journal of Medicine Confirm On-Label, Long-Term Safety and Efficacy of the CYPHER(R) Sirolimus-Eluting Coronary Stent Compared to Bare Metal Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Dec 2006
American Heart Association Statement on Use of Drug-Eluting Coronary Stents
Devices Interventional Cardiology
 HSMN NewsFeed - 30 Nov 2006
Patent and 3f Acquisition Strengthen ATS Medical's Intellectual Property Portfolio
Devices
 HSMN NewsFeed - 13 Nov 2006
Volcano Announces Clinical Review of Key Presentations From TCT 2006
Devices Interventional Cardiology
 HSMN NewsFeed - 1 Nov 2006
MediciNova Announces the Acquisition of Two Novel Antithrombotic Agents from Meiji Seika Kaisha, Ltd.
Biopharmaceuticals Cardiology Acquisitions
 HSMN NewsFeed - 26 Oct 2006
Lipicard's Platrol(R) - First Safe, Sustained Release Antiplatelet Drug Developed Through a Novel Platform Technology
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 24 Oct 2006
Cordis to Study Impact of Contributing Factors to Stent Thrombosis in Expansion of 30,000-Stent Patient Registry
Devices Interventional Cardiology
 HSMN NewsFeed - 19 Oct 2006
Medtronic Announces Largest Clinical Study Evaluating Drug-Eluting Stent Safety
Devices Interventional Cardiology
 HSMN NewsFeed - 10 Jul 2006
ARCA Discovery, Inc. Names Dr. Ann Lenich Hards Executive Vice President Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 May 2006
Merck Announces Preliminary Analyses of Off-Drug Extension of APPROVe Study
Biopharmaceuticals Oncology Cardiology
 HSMN NewsFeed - 11 May 2006
Conor Medsystems Initiates RAPID Clinical Study for First Pimecrolimus Drug-Eluting Stent
Devices Interventional Cardiology
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
anti-platelet
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.